Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 3/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | CBX4 | O00257 | 2/20 | 0.42 |
| ▸ | CBX7 | O95931 | 2/20 | 0.42 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.42 |
| ▸ | CBX8 | Q9HC52 | 2/20 | 0.42 |
| ▸ | EPOR | P19235 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613487 | 0.90 | CDYL2 (0.48) | CBX4CBX7CDYL2CBX8SIRT2 | |
| SCHEMBL29129114 | 0.89 | CA2 (0.47) | ROCK2TLR2CA2PRKACAAKT3 | |
| SCHEMBL29613403 | 0.85 | KMT2A (0.41) | TLR2CBX4CBX7CDYL2CBX8 | |
| SCHEMBL29129144 | 0.79 | CBX4 (0.44) | CBX4CBX7CDYL2CBX8SIRT2 | |
| SCHEMBL23475254 | 0.78 | SIRT2 (0.46) | TLR2CPB1CPB2SIRT2SIRT1 | |
| SCHEMBL29129094 | 0.77 | KMT2A (0.43) | TLR2TPSAB1 | |
| SCHEMBL23447173 | 0.76 | MEN1 (0.44) | ROCK2TLR2CPB1CPB2EPOR | |
| SCHEMBL29613443 | 0.76 | CDYL2 (0.70) | CPB1CPB2CBX4CBX7CDYL2 | |
| SCHEMBL23446284 | 0.72 | MEN1 (0.49) | TLR2 | |
| SCHEMBL22301191 | 0.72 | MEN1 (0.45) | TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | ROCK2 4110/4885TLR2 4702/4885CPB1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.